



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
'NEELAM CENTRE', 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAND DOCTORS' RD, MUMBAI,
PHONE : 022-3045 1500 / 3045 1200
FAX : 022 2493 0534 / 2493 9633
<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:386

November 1, 2012

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Unaudited Financial Results for the quarter/half year ended on
September 30, 2012

Enclosed please find unaudited financial results for the quarter/half year
ended on September 30, 2012. These financial results have been approved and
taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,
for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary - General Manager

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

'NEELAM CENTRE', 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30/09/2012

Sl. No.	PART I - Particulars	(Rs. in lakhs)					
		Quarter ended			Half Year		Year ended
		30/09/2012	30/06/2012	30/09/2011	30/09/2012	30/09/2011	31/03/2012
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a. Net sales (Net of excise duty)	21,212.46	18,484.71	16,077.14	39,697.17	33,821.55	63,577.48
	b. Other Operating Income	511.72	489.79	3,287.93	1,001.51	3,800.03	5,064.65
	Total Income from Operations (Net) (a+b)	21,724.18	18,974.50	19,365.07	40,698.68	37,621.58	68,642.13
2	Expenses						
	a. Cost of materials consumed	7,337.08	6,132.79	5,718.18	13,469.87	10,828.09	20,320.53
	b. Purchases of stock-in-trade	1,711.79	1,396.77	1,572.78	3,108.56	2,793.98	6,999.76
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	216.10	354.55	249.98	570.65	659.72	(547.18)
	d. Employees benefits expense	2,892.84	3,079.53	2,130.96	5,972.37	5,241.26	10,131.32
	e. Depreciation and amortization expense	612.65	601.35	567.50	1,214.00	1,135.00	2,238.40
	f. Exchange Fluctuation Transactional (Gain)/Loss	136.61	895.92	(261.86)	1,032.53	(271.91)	1,736.63
	g. Other Expenses	6,245.95	5,116.76	5,316.91	11,362.71	10,439.73	22,276.72
	Total Expenses	19,153.02	17,577.67	15,294.45	36,730.69	30,825.07	63,148.18
3	Profit/(Loss) from Operations before Other Income, Finance Cost and exceptional item (1-2)	2,571.16	1,396.83	4,070.62	3,967.99	6,795.71	5,493.95
4	Other Income	1,368.40	270.01	1,361.63	1,638.41	1,779.96	2,051.19
5	Profit/(Loss) from Ordinary Activities before Finance Cost and exceptional item (3+4)	3,939.56	1,666.84	5,432.25	5,606.40	8,575.67	8,345.14
6	Finance Cost	95.66	124.13	910.35	219.79	1,128.01	2,163.97
7	Profit/(Loss) from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	3,843.90	1,542.71	4,521.90	5,386.61	7,447.66	6,101.17
8	Exchange Fluctuation Translation Gain / (Loss)	942.55	(961.77)	(1,316.29)	(19.22)	(1,553.82)	(1,318.27)
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional item (7+8)	4,786.45	580.94	3,205.61	5,367.39	5,893.04	4,862.90
10	Exceptional Item	0.00	0.00	76,059.34	0.00	76,059.34	76,059.34
11	Profit from Ordinary Activities before Tax (9+10)	4,706.45	500.94	79,264.95	5,367.39	61,953.18	80,922.24
12	Tax expenses	886.08	150.09	17,269.61	1,036.17	18,052.92	16,652.30
13	Net Profit for the period from Ordinary Activities after Tax (11-12)	3,900.37	430.85	61,995.34	4,331.22	63,900.26	64,269.94
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,694.15	1,694.15	1,694.10	1,694.15	1,694.10	1,694.15
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	93,692.17
16	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	4.60	0.51	73.30	5.11	75.56	75.95
	(2) Diluted	4.60	0.51	73.15	5.11	75.39	75.95

Sl. No.	PART II - Particulars	Quarter ended			Half Year		Year ended
		30/09/2012	30/06/2012	30/09/2011	30/09/2012	30/09/2011	31/03/2012
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	37,380,603	37,380,603	37,850,710	37,380,603	37,850,710	37,380,603
	- Percentage of shareholding	44.13	44.13	44.69	44.13	44.69	44.13
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered	-	-	-	-	-	-
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	47,326,697	47,326,697	46,854,090	47,326,697	46,854,090	47,326,697
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.87	55.87	55.31	55.07	55.31	55.87

8 INVESTOR COMPLAINTS

Particulars	3 Months ended 30/09/2012
Pending at the beginning of the quarter	Nil
Received during the quarter	8
Disposed of during the quarter	8
Remaining unresolved at the end of the quarter	Nil



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE" B WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORSAID, MUMBAI.

PHONE : 022 3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

HTTP : www.uniduepharma.com

NOTES

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on November 1, 2012.
2. The statutory auditors have carried out a limited review of the above unaudited financial results for the quarter and half year ended on September 30, 2012.
3. The figures for the quarter/half year are strictly not comparable with the corresponding quarter/half year in the previous year consequent to sale of Russia-CIS OTC business undertaking on July 14, 2011.
4. The company has received notices of claim from Johnson & Johnson affiliates under transaction documents executed by the company/its subsidiary with them in relation to sale of Russia/CIS OTC Business Undertaking. The claims received correspond to the amount held in the Escrow Account. The company believes that these claims are untenable and accordingly the company has responded by way of denial of the claims and has submitted a detailed rejoinder to such claims.
5. The company is engaged in a single segment of activity namely, "Pharmaceuticals".
6. Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary.
7. The statement of assets and liabilities as of September 30, 2012 is as under:

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

Sl. No.	Particulars	As at 30/09/2012	As at 31/03/2012
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a. Share Capital	1,694.15	1,694.15
	b. Reserves and surplus	98,017.30	93,692.17
	Sub Total of Shareholders' funds	99,711.45	95,386.32
2	Non-current liabilities		
	a. Long-term borrowings	838.66	1,152.17
	b. Deferred tax liabilities (Net)	1,911.69	1,655.69
	c. Long-term provisions	935.36	826.84
	Sub-Total - Non-current liabilities	3,685.71	3,634.70
3	Current liabilities		
	a. Short-term borrowings	3,782.42	5,522.65
	b. Trade payables	4,192.31	3,353.77
	c. Other current liabilities	9,278.88	7,669.74
	d. Short-term provisions	928.14	1,704.53
	Sub-Total - Current liabilities	18,181.75	18,250.69
	TOTAL-EQUITY AND LIABILITIES	121,578.91	117,271.71
8	ASSETS		
1	Non-current assets		
	a. Fixed assets	29,038.13	28,000.53
	b. Non-current investments	3,884.53	3,878.98
	c. Long-term loans and advances	1,516.62	1,258.29
	d. Other non-current assets	1,000.53	708.30
	Sub-Total - Non-current assets	35,439.81	33,846.10
2	Current assets		
	a. Current investments	32,526.63	29,892.18
	b. Inventories	8,844.45	9,079.85
	c. Trade receivables	18,229.87	13,120.82
	d. Cash and cash equivalents	19,023.11	21,136.24
	e. Short-term loans and advances	7,515.04	10,196.52
	Sub-Total - Current assets	86,139.10	83,425.61
	TOTAL-ASSETS	121,578.91	117,271.71

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody
Chairman & Managing Director

Place : Mumbai

Date : November 1, 2012